IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 18/05/2020 - General information

    The version 7.0 of DisGeNET is now available and includes the creation of a new resource for COVID-19

    The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET (version 7.0, May 8, 2020), which contains more than 1 million associations between 21,000 genes and 30,000 diseases, and 350,000 associations involving more than 190,000 genomic variants. All the data sources have been updated including the information automatically extracted by text mining of the literature. In addition, a new resource focused on COVID-19 has also been created. DisGeNET is a public knowledge management platform that offers information on genes and genomic variants associated with human diseases, which is obtained by integrating data from more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available and is a resource for sharing and exchanging information recommended by the ELIXIR project, which is called, ELIXIR Recommended Interoperability Resource.

    Més informació "The version 7.0 of DisGeNET is now available and includes the creation of a new resource for COVID-19"

  • 06/05/2020 - Press release

    The FDA licenses Chemotargets CLARITY platform

    The Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has licensed the Chemotargets CLARITY® platform for predicting unknown secondary targets for new molecules of pharmaceutical interest. This contract is meant to directly address the FDA's requirement for a computational method which can predict potential molecular targets from chemical structure and provide a user-friendly environment for analysis of results. Molecular targets identified with high confidence by CLARITY® may be evaluated by FDA/CDER for their association with adverse events, addiction liability, or their association with disease within the specified indication(s).

    Més informació "The FDA licenses Chemotargets CLARITY platform"

  • 17/04/2020 - Press release

    Chemotargets opens an investment round to enter a new phase of growth

    Chemotargets, a global leader in predictive analytics solutions for the pharma and biotech sector, begins a phase of transformation to become a biotechnology company that will develop new medicines in multiple therapeutic areas, with an initial focus on oncology. Founded in 2006 as a spin-off from Dr. Jordi Mestres' Systems Pharmacology lab under the auspices of the IMIM Hospital del Mar Medical Research Institute, a leading academic centre of excellence based in Barcelona, Chemotargets is opening an investment round to undertake the transformation of its business model. Genesis Biomed, a well-established consultancy firm in the health and biotech sectors, and CREA Inversión, an M&A boutique advisory firm specialised in corporate transactions and financing, will advise Chemotargets in this transformation.

    Més informació "Chemotargets opens an investment round to enter a new phase of growth"

  • 06/02/2020 - Press release

    The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases

    Ten years ago, researchers at Hospital del Mar Medical Research Institute (IMIM) and at Pompeu Fabra University (UPF) created a computer platform for collecting highly relevant scientific information that had, until then, been scattered across several sources: relationships between genes and diseases. This open access tool called DisGeNET has become a benchmark in the field of research. From now on, it will also have an industrial application thanks to MedBioinformatics Solutions, a spin-off of IMIM and UPF that is to develop software and consulting services that will bring added value to the information of DisGeNET to help companies develop new products and services. The company came to life today, 6 February, with the signing of the deeds of incorporation by the acting director of IMIM, Jorge Martínez, the UPF general manager, Jaume Badia; the researchers and partners of the company, Ferran Sanz, Laura Furlong, Janet Piñero and Olga Valverde, and the investor partners: Frederic Abelló and the companies Prous Institute for Biomedical Research and Icrowd+D.

    Més informació "The spin-off MedBioinformatics Solutions is born to offer software and consultancy on relationships between genes and diseases"

  • 27/11/2019 - Press release

    Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)

    Outstanding women researchers who use the latest computer advances for biomedical research and directives from companies and institutions in the world of technology and biomedicine will present the latest developments in this field of research and discuss the most immediate challenges at the end of November in Barcelona. The meeting will take place during the first edition of the Advances in Computational Biology (AdvCompBio) conference, which will gather around 200 attendees in the auditorium of La Pedrera in Barcelona on November 28 and 29. In this conference, all speakers and organizers are women, although the sessions will be open to everyone. AdvCompBio is primarily a high-level international scientific meeting, intended to discuss the latest artificial intelligence and big data technologies in computational biology, promote the exchange of experiences and create collaborative networks.

    Més informació "Women researchers and directives explain the latest advances in artificial intelligence, big data and other technologies used in biomedical research (Press release sent byBSC)"

  • 08/10/2019 - Press release

    Our own bodies hold the key to designing safer drugs

    Based on a study of 566 drugs that interact with 129 different proteins, researchers from the Systems Pharmacology research group, part of the GRIB Research Programme on Biomedical Informatics, a joint programme between the Hospital del Mar Medical Research Institute (IMIM) and Pompeu Fabra University (UPF), in collaboration with researchers from the University of New Mexico, in the United States, realised that 71% of drugs have stronger affinities for their target proteins than those of the small internal molecules responsible for regulating their functions. Surprisingly, this is the first time that the affinities of endogenous ligands and drugs for the same proteins have been quantified. Humans have thousands of proteins, each with a specific function that is often regulated by thousands of small molecules synthesised by our bodies. This set of small molecules, also known as "endogenous metabolites", is known as the "human metabolome". Each one interacts with its native protein with a certain affinity that has been carefully optimised, in a natural way, throughout the long process of evolution, and this can vary between species and even in some instances, more subtly, between individuals.

    Més informació "Our own bodies hold the key to designing safer drugs"

  • 13/05/2019 - Events

    A conference to promote women's research in computational biology

    BSC, UPC and IMIM organize the first Advances in Computational Biology conference will bring together researchers working on systems biology, omics technologies, artificial intelligence and high-performance computing (HPC) with applications to biology from both the public and the private sectors. The conference will be held November 28-29 in La Pedrera (Barcelona). Maria Jose Rementeria, Social Link Analytics group leader at the Barcelona Supercomputing Center (BSC) and one of the organizers, states: "One of the main purposes of the conference is to visualize and promote the research done by women scientists and for this reason all presenters will be women, although the conference is open to everyone. We want to create a space to foster collaborations between scientists, providing a unique opportunity to share ideas and build research networks".

    Més informació "A conference to promote women's research in computational biology"

  • 09/05/2019 - General information

    New version of DisGeNET 6.0 and ELIXIR recognition

    The GRIB Integrative Biomedical Informatics group (IMIM-UPF) has launched a new version of DisGeNET, a public knowledge management platform on the genomics of disease, which is celebrating its tenth anniversary this year. DisGeNET offers information on genes and genomic variants associated with human diseases, which is obtained by integrating more than a dozen public resources and the scientific literature. DisGeNET contains one of the most comprehensive collections of genes and variants associated with human diseases that is currently available. The new version of DisGeNET (6.0) contains approximately 600,000 associations between more than 17,000 genes and 24,000 human diseases, focusing particularly on genetic alterations associated with disease: this version includes more than 117,000 genomic variants associated with 10,000 diseases. In addition, the phenotypic landscape covered by DisGeNET has been expanded to include the genomic basis of clinical manifestations of diseases, both signs and symptoms, as well as laboratory tests results.

    Més informació "New version of DisGeNET 6.0 and ELIXIR recognition"

  • 10/04/2019 - General information

    Jordi Mestres takes part in the European project EOSC-Life which aims to develop an open collaborative space for digital biology

    The project EOSC-Life aims to create an open collaborative digital space for life science in the European Open Science Cloud (EOSC). EOSC-Life brings together the 13 european research infrastructures in the Health and Food domain of the ESFRI Roadmap and is funded by H2020 for the period 2019-2023. The project involves research groups from 46 European academic institutions. These include the GRIB Systems Pharmacology research group (IMIM-UPF) led by Jordi Mestres, which is helping develop collaborative tools for integrating and analysing all kinds of data in the field of life sciences.

    Més informació "Jordi Mestres takes part in the European project EOSC-Life which aims to develop an open collaborative space for digital biology"

  • 11/07/2018 - Press release

    A new computational method for exploring the reuse of drugs

    Researchers led by Emre Guney of the research programme on Biomedical Informatics (GRIB), a joint programme of Pompeu Fabra University (UPF) and the Hospital del Mar Medical Research Institute (IMIM), have developed a new computational method to reuse drugs that target biological pathways common to more than one disease. A significant percentage of marketed drugs are not effective in patients due to the complexity of the biological processes involved in diseases and genetic differences between people. Despite recent technological advances, the discovery of new effective treatments takes a long time and continues to be expensive. For this reason, the reuse of medicines, i.e., the use of existing drugs for other diseases, is a very interesting alternative to reduce the costs of drug development.

    Més informació "A new computational method for exploring the reuse of drugs"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact